> One of my problems with this study (and many preliminary medical intervention studies hyped mostly by press releases) is that it deals with a biomarker--telom

> One of my problems with this study (and many preliminary medical intervention studies hyped mostly by press releases) is that it deals with a biomarker--telomere length--rather than with a hard endpoint, for example actual improved cancer survival and reduced all-cause mortality in the patients. That is not an issue with the study's quality. It is more of an issue with the study's motive (goal?).